Tuberculosis Diagnostics Market By Test Type (Sputum Smear Microscopy, Culture-Based Tests, Nucleic Acid Amplification Tests (NAATs), Serological Tests, Mantoux Tuberculin Skin Test (TST), Interferon-Gamma Release Assays (IGRAs)), By End User (Hospitals & Clinics, Diagnostic Laboratories, Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Tuberculosis Diagnostics Market was valued at USD 1.9 billion in 2024-e and will surpass USD 3.2 billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

The tuberculosis (TB) diagnostics market is witnessing steady growth due to the increasing global burden of TB and the rising need for early and accurate detection methods. With tuberculosis remaining a major public health concern, especially in developing countries, governments and healthcare organizations are focusing on strengthening TB surveillance and diagnostic capabilities. Advances in molecular diagnostics, improved laboratory infrastructure, and the introduction of point-of-care testing solutions are contributing to the expansion of the market.

The growing adoption of rapid diagnostic techniques, such as nucleic acid amplification tests (NAATs) and interferon-gamma release assays (IGRAs), is transforming TB detection by providing higher accuracy and faster turnaround times compared to traditional methods. Additionally, ongoing research into novel biomarkers and AI-powered diagnostic tools is expected to enhance the efficiency of tuberculosis diagnosis in the coming years.

Nucleic Acid Amplification Tests (NAATs) Lead Due to Their High Sensitivity and Rapid Results

Nucleic acid amplification tests (NAATs) have emerged as the leading test type in the tuberculosis diagnostics market due to their superior accuracy, speed, and ability to detect drug-resistant TB strains. NAATs, including polymerase chain reaction (PCR)-based techniques, offer a significant advantage over traditional culture-based and microscopy tests by providing results within a few hours, making them ideal for early diagnosis and treatment initiation.

The increasing demand for molecular diagnostic solutions, particularly in high-TB-burden regions, is driving the adoption of NAATs. Technological advancements such as automated real-time PCR systems and portable point-of-care NAAT platforms are further accelerating market growth. As global TB control programs emphasize rapid and precise diagnostic methods, NAATs are expected to play a crucial role in improving tuberculosis detection rates.

Hospitals & Clinics Remain the Largest End Users Due to High Patient Volume

Hospitals and clinics dominate the tuberculosis diagnostics market, as they are the primary healthcare facilities for TB screening, diagnosis, and treatment. These institutions have access to advanced diagnostic technologies, experienced healthcare professionals, and well-equipped laboratories, enabling them to conduct a wide range of TB tests, from sputum smear microscopy to molecular assays.

The increasing integration of TB diagnostic services within hospital settings, particularly in endemic regions, has contributed to market growth. Government-led TB control programs and funding initiatives for hospital-based diagnostics further support the expansion of this segment. With the growing emphasis on early detection and improved patient management, hospitals and clinics will continue to play a vital role in the tuberculosis diagnostics landscape.

Asia-Pacific Holds the Largest Market Share Due to High TB Prevalence and Government Initiatives

Asia-Pacific leads the global tuberculosis diagnostics market, primarily due to the high burden of TB cases in countries such as India, China, Indonesia, and the Philippines. The region's strong focus on TB elimination programs, supported by government and non-government organizations, has led to increased investments in diagnostic infrastructure, rapid testing technologies, and research initiatives.

The rising awareness of TB, along with improvements in healthcare accessibility and laboratory facilities, is further driving market growth in Asia-Pacific. International collaborations, such as partnerships with the World Health Organization (WHO) and the Global Fund, are helping countries in this region enhance TB detection and treatment capabilities. As nations continue to adopt advanced diagnostic methods and strengthen disease surveillance systems, Asia-Pacific is expected to maintain its leadership in the tuberculosis diagnostics market.

Competitive Landscape and Key Players

The tuberculosis diagnostics market is highly competitive, with leading companies focusing on technological advancements, strategic partnerships, and expanded access to rapid testing solutions. Key players such as Cepheid Inc., Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company are investing in the development of next-generation TB diagnostic technologies, including AI-driven detection tools and portable molecular testing platforms.

Collaborations between governments, non-profit organizations, and diagnostic companies are playing a critical role in improving global TB detection rates. As innovations in TB diagnostics continue to evolve, the market is expected to witness significant advancements in speed, accuracy, and accessibility, ultimately contributing to more effective TB control and elimination efforts worldwide.

List of Leading Companies:

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• Hologic, Inc.
• BioMérieux SA
• Cepheid (Danaher Corporation)
• QIAGEN N.V.
• Siemens Healthineers
• PerkinElmer, Inc.
• Luminex Corporation
• Oxford Immunotec
• Akonni Biosystems, Inc.
• Creative Diagnostics
• GenMark Diagnostics

Recent Developments:

• In January 2025, Cepheid launched a next-generation rapid NAAT for tuberculosis diagnosis.
• In December 2024, Abbott Laboratories introduced an AI-integrated TB detection system.
• In November 2024, BioMérieux SA expanded its TB testing portfolio with a new serological assay.
• In October 2024, Siemens Healthineers partnered with global health organizations to improve TB diagnostic accessibility.
• In September 2024, Becton, Dickinson and Company announced an upgraded automated culture-based TB test for improved detection.

Report Scope: